Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qualigen Therapeutics ( (QLGN) ) has provided an update.
On September 15, 2025, Qualigen Therapeutics, Inc. amended its Secured Demand Promissory Note with Marizyme, Inc., adjusting the maturity date to August 21, 2026, and increasing the principal amount by $75,000 to a total of $4,526,462.18. This amendment ensures the company’s obligations remain secured and reflects a strategic financial adjustment, potentially impacting its financial stability and stakeholder interests.
Spark’s Take on QLGN Stock
According to Spark, TipRanks’ AI Analyst, QLGN is a Underperform.
Qualigen Therapeutics’ overall stock score is low due to significant financial challenges, including declining revenue, substantial losses, and financial instability. The bearish technical analysis further dampens the outlook. However, recent corporate events like strategic investments and leadership changes provide a slight positive outlook on future potential improvements.
To see Spark’s full report on QLGN stock, click here.
More about Qualigen Therapeutics
Average Trading Volume: 856,716
Technical Sentiment Signal: Sell
Current Market Cap: $3.44M
For an in-depth examination of QLGN stock, go to TipRanks’ Overview page.